137 related articles for article (PubMed ID: 9096672)
1. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts.
Sharma A; Mayhew E; Bolcsak L; Cavanaugh C; Harmon P; Janoff A; Bernacki RJ
Int J Cancer; 1997 Mar; 71(1):103-7. PubMed ID: 9096672
[TBL] [Abstract][Full Text] [Related]
2. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.
Sharma A; Straubinger RM; Ojima I; Bernacki RJ
J Pharm Sci; 1995 Dec; 84(12):1400-4. PubMed ID: 8748320
[TBL] [Abstract][Full Text] [Related]
3. Novel taxol formulations: preparation and characterization of taxol-containing liposomes.
Sharma A; Straubinger RM
Pharm Res; 1994 Jun; 11(6):889-96. PubMed ID: 7937531
[TBL] [Abstract][Full Text] [Related]
4. Novel Taxol formulations: Taxol-containing liposomes.
Straubinger RM; Sharma A; Murray M; Mayhew E
J Natl Cancer Inst Monogr; 1993; (15):69-78. PubMed ID: 7912532
[TBL] [Abstract][Full Text] [Related]
5. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
Tong L; Chen W; Wu J; Li H
Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
[TBL] [Abstract][Full Text] [Related]
6. Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel.
Chou TC; Zhang XG; Harris CR; Kuduk SD; Balog A; Savin KA; Bertino JR; Danishefsky SJ
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15798-802. PubMed ID: 9861050
[TBL] [Abstract][Full Text] [Related]
7. Liposome formulation of paclitaxel with enhanced solubility and stability.
Yang T; Cui FD; Choi MK; Lin H; Chung SJ; Shim CK; Kim DD
Drug Deliv; 2007 Jul; 14(5):301-8. PubMed ID: 17613018
[TBL] [Abstract][Full Text] [Related]
8. Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma.
Auzenne E; Donato NJ; Li C; Leroux E; Price RE; Farquhar D; Klostergaard J
Clin Cancer Res; 2002 Feb; 8(2):573-81. PubMed ID: 11839679
[TBL] [Abstract][Full Text] [Related]
9. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel.
Ceruti M; Crosasso P; Brusa P; Arpicco S; Dosio F; Cattel L
J Control Release; 2000 Jan; 63(1-2):141-53. PubMed ID: 10640588
[TBL] [Abstract][Full Text] [Related]
10. A mixed micellar formulation suitable for the parenteral administration of taxol.
Alkan-Onyuksel H; Ramakrishnan S; Chai HB; Pezzuto JM
Pharm Res; 1994 Feb; 11(2):206-12. PubMed ID: 7909371
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.
Liu X; Sun J; Chen X; Wang S; Scott H; Zhang X; Zhang Q
J Pharm Pharmacol; 2012 Jun; 64(6):775-82. PubMed ID: 22571255
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model.
Sharma A; Mayhew E; Straubinger RM
Cancer Res; 1993 Dec; 53(24):5877-81. PubMed ID: 7903197
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice.
Nicoletti MI; Lucchini V; Massazza G; Abbott BJ; D'Incalci M; Giavazzi R
Ann Oncol; 1993 Feb; 4(2):151-5. PubMed ID: 8095399
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effect and toxicity of Lipusu in rat ovarian cancer xenografts.
Ye L; He J; Hu Z; Dong Q; Wang H; Fu F; Tian J
Food Chem Toxicol; 2013 Feb; 52():200-6. PubMed ID: 23149094
[TBL] [Abstract][Full Text] [Related]
15. Thermosensitive liposomal taxol formulation: heat-mediated targeted drug delivery in murine melanoma.
Sharma D; Chelvi TP; Kaur J; Ralhan R
Melanoma Res; 1998 Jun; 8(3):240-4. PubMed ID: 9664145
[TBL] [Abstract][Full Text] [Related]
16. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract][Full Text] [Related]
17. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
Cancer Res; 1996 May; 56(9):2112-5. PubMed ID: 8616858
[TBL] [Abstract][Full Text] [Related]
18. Growth inhibition of a human ovarian tumor by a novel paclitaxel derivative in SCID mice.
Ahmad I; Masters GR; Schupsky JJ; Nguyen J; Ali S; Janoff AS; Mayhew E
Oncol Res; 1999; 11(6):273-80. PubMed ID: 10691029
[TBL] [Abstract][Full Text] [Related]
19. Effects of free and liposome-encapsulated taxol on two brain tumors xenografted into nude mice.
Riondel J; Jacrot M; Fessi H; Puisieux F; Potier
In Vivo; 1992; 6(1):23-7. PubMed ID: 1352706
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel.
Zhang X; Burt HM; Mangold G; Dexter D; Von Hoff D; Mayer L; Hunter WL
Anticancer Drugs; 1997 Aug; 8(7):696-701. PubMed ID: 9311446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
